As of close of business last night, 4D Molecular Therapeutics Inc’s stock clocked out at $26.25, down -0.38% from its previous closing price of $26.35. On the day, 610526 shares were traded.
Ratios:
To gain a deeper understanding of FDMT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 18.07 and its Current Ratio is at 18.07. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on April 15, 2024, initiated with a Overweight rating and assigned the stock a target price of $459.
On April 15, 2024, Barclays started tracking the stock assigning a Overweight rating and target price of $45.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 01 ’24 when Bizily Scott sold 8,153 shares for $31.78 per share. The transaction valued at 259,102 led to the insider holds 1,737 shares of the business.
Bizily Scott sold 5,833 shares of FDMT for $204,410 on Mar 27 ’24. The Chief Legal Officer now owns 1,737 shares after completing the transaction at $35.04 per share. On Mar 18 ’24, another insider, Bizily Scott, who serves as the Chief Legal Officer of the company, sold 1,750 shares for $31.27 each. As a result, the insider received 54,722 and left with 1,737 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 59.42 while its Price-to-Book (P/B) ratio in mrq is 3.40.
Stock Price History:
Over the past 52 weeks, FDMT has reached a high of $36.25, while it has fallen to a 52-week low of $9.44.
Shares Statistics:
A total of 49.78M shares are outstanding, with a floating share count of 43.64M. Insiders hold about 12.33% of the company’s shares, while institutions hold 74.94% stake in the company.
Earnings Estimates
As of right now, FDHT analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $26.25, with high estimates of $0.04 and low estimates of $0.01.
Analysts are recommending an EPS of between $Communication Services and $Financial Services for the fiscal current year, implying an average EPS of $Healthcare.
